ROB Insight is a premium commentary product offering rapid analysis of business and economic news, corporate strategy and policy, published throughout the business day. Visit the ROB Insight homepage for analysis available only to subscribers.
If I told you there is a top-performing equity market sector with mammoth and sustainable profit margins, demographic tail winds, earnings growth well above the market average and which is largely immune from a slowing global economy, you’d suspect that investors had already taken on large positions. But this is not the case. The U.S. biotechnology sector continues to receive minimal attention despite outsized returns and a promising outlook.